“The North America intrauterine contraceptive devices market is estimated to grow at a CAGR of 0.3% from 2014 to 2019. The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of the Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing expenses related to abortion, funds/grants for IUCD products, and technological advancements. However, high costs of treatment, threat of pelvic inflammatory infection (PID), threat of ectopic pregnancy, high rate of complications during unplanned pregnancy, and the need for compulsory assistance of medical professionals hamper the growth of the IUCD market. Moreover, the rising number of players in this segment and technological advancements create growth opportunities for the North America intrauterine contraceptive devices market in these regions.
In this report, the North America intrauterine contraceptive devices market has been broadly classified on the basis of types, which includes Hormonal IUCD and Copper IUCD. The hormonal IUCD market segment accounted for the largest market share of 83.4% of the North American intrauterine contraceptive devices market. Factors such as safety, easy removal, lighter periods, and the increasing adoption of hormonal IUD products such as Mirean and Skyla in the U.S. drive the growth of this market.
Geographically, the U.S. is estimated to command the largest share of 93.0% of the North America intrauterine contraceptive devices market in 2014, followed by Canada. The intrauterine contraceptive devices market in the U.S. is primarily driven by the Affordable Care Act and technological advancements. However, stringent regulatory and reimbursement policies in the U.S. and the threat of PID infection hamper the growth of the intrauterine contraceptive devices market in this region.
The North America intrauterine contraceptive devices market is a competitive market with a number of market players. As of 2014, the North America intrauterine contraceptive devices market is estimated to be dominated by Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and Medicines360 (Ireland). New product launches & partnerships, agreements, collaborations, and joint ventures are the major strategies adopted by most market players to achieve growth in the North America intrauterine contraceptive devices market.
Reasons to Buy the Report:
From an insight perspective, this research report has focused on various levels of analysis—market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging- and high-growth segments of the North America intrauterine contraceptive devices market, high-growth regions & countries & their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.
The report will enrich both the established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms that purchase the report could use any one or a combination of five strategies that include market penetration, product development/innovation, market development, market diversification, and competitive assessment to strengthen their market share.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on intrauterine contraceptive devices offered by top players in the North America intrauterine contraceptive devices market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the North America intrauterine contraceptive devices market.
• Market Development: Comprehensive information of lucrative emerging markets. The report analyzes the markets for various intrauterine contraceptive devices across geographies.
• Market Diversification: Exhaustive information of new products, untapped geographies, recent developments, and investments in the North America intrauterine contraceptive devices market.
• Competitive Assessment: In-depth assessment of the market shares, strategies, products, and manufacturing capabilities of leading players in the North America intrauterine contraceptive devices market.
”
“TABLE OF CONTENTS
1 INTRODUCTION 8
1.1 OBJECTIVES OF THE STUDY 9
1.2 MARKET SEGMENTATION & COVERAGE 10
2 RESEARCH METHODOLOGY 11
2.1 INTEGRATED ECOSYSTEM OF INTRAUTERINE CONTRACEPTIVE DEVICES MARKET 11
2.2 ARRIVING AT THE INTRAUTERINE CONTRACEPTIVE DEVICES MARKET SIZE 12
2.2.1 TOP-DOWN APPROACH 12
2.2.2 BOTTOM-UP APPROACH 12
2.2.3 MACRO INDICATOR-BASED APPROACH 14
2.3 ASSUMPTIONS 14
3 EXECUTIVE SUMMARY 16
4 MARKET OVERVIEW 18
4.1 INTRODUCTION 18
4.2 MARKET DRIVERS and INHIBITORS 19
4.3 KEY MARKET DYNAMICS 23
5 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 26
5.1 INTRODUCTION 27
5.2 COPPER IUD 27
5.3 HORMONAL IUD 28
5.4 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET 29
5.5 NORTH AMERICA hormonal iud MARKET, BY country 30
5.6 NORTH AMERICA COPPER IUD MARKET, BY COUNTRY 31
6 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY PRODUCT 32
6.1 MIRENA 32
6.1.1 PRODUCT POSITIONING AND PROMOTIONS OF MIRENA 33
6.2 SKYLA 34
6.2.1 PRODUCT POSITIONING AND PROMOTIONS OF SKYLA 35
6.3 PARAGARD 36
6.3.1 PRODUCT POSITIONING AND PROMOTIONS OF PARAGARD 37
6.4 ESSURE 38
6.4.1 PRODUCT POSITIONING AND PROMOTIONS OF ESSURE 38
6.5 PIPELINE PRODUCTS 39
6.5.1 LEVOSERT 40
7 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET,
BY GEOGRAPHY 42
7.1 INTRODUCTION 43
7.2 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET 44
7.2.1 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY TYPE 45
7.2.2 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 47
7.3 CANADA intra-uterine contraceptice devices MARKET 49
7.3.1 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 50
8 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPETITIVE LANDSCAPE 51
8.1 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS 51
8.2 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS 52
8.3 MERGERS & ACQUISITIONS 53
8.4 REGULATORY APPROVALS 53
8.5 PARTNERSHIP 54
8.6 COLLABORATION 54
9 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY COMPANY 55
9.1 BAYER HEALTHCARE AG (SUBSIDIARY OF BAYER AG) 55
9.1.1 OVERVIEW 55
9.1.2 KEY FINANCIALS 56
9.1.3 PRODUCT PORTFOLIO 56
9.1.4 RELATED DEVELOPMENTS 57
9.1.5 SWOT ANALYSIS 58
9.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 59
9.2.1.1 OVERVIEW 59
9.2.2 PRODUCT PORTFOLIO 60
9.2.3 SWOT ANALYSIS 61
9.3 ACTAVIS PLC 62
9.3.1 OVERVIEW 62
9.3.2 PRODUCT AND SERVICE OFFERINGS 63
9.3.3 RELATED DEVELOPMENTS 63
9.4 MEDICINES360 64
9.4.1 OVERVIEW 64
9.4.2 FINANCIALS 64
9.4.3 PRODUCT AND SERVICE OFFERINGS 64
9.4.4 RELATED DEVELOPMENTS 64
9.5 TRIMEDIC SUPPLY NETWORK LTD. 65
9.5.1 OVERVIEW 65
9.5.2 FINANCIALS 65
9.5.3 PRODUCTS AND SERVICE OFFERINGS 65
9.6 MEDISAFE DISTRIBUTION INC. 66
9.6.1 OVERVIEW 66
9.6.2 FINANCIALS 66
9.6.3 PRODUCT AND SERVICES OFFERINGS 66
9.6.4 RELATED DEVELOPMENTS 66
9.7 PACE PHARMACEUTICALS, INC. 67
9.7.1 OVERVIEW 67
9.7.2 FINANCIALS 67
9.7.3 PRODUCTS 67
9.7.4 RELATED DEVELOPMENTS 67
10 APPENDIX 68
10.1 RELATED REPORTS 68
10.2 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 68
10.2.1 RT SNAPSHOTS 69
“LIST OF TABLES
UU
TABLE 1 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: MACRO INDICATORS, BY COUNTRY, 2013 (ABORTION PER 1000 WOMEN AGES 15-44) 14
TABLE 2 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: DRIVERS AND INHIBITORS 19
TABLE 3 GLOBAL INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPARISION WITH GLOBAL FEMALE CONTRACEPTIVES MARKET, 2013–2019 (USD MN) 23
TABLE 4 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY COUNTRY, 2013–2019 (USD MN) 24
TABLE 5 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYP,
2013–2019 (USD MN) 25
TABLE 6 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2013–2019 (USD MN) 29
TABLE 7 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET, 2013–2019 (USD MN) 30
TABLE 8 NORTH AMERICA HORMONAL IUD MARKET, BY COUNTRY, 2013–2019 (USD MN) 30
TABLE 9 NORTH AMERICA COPPER IUD MARKET, BY COUNTRY, 2012 – 2018 (USD MN) 31
TABLE 10 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BYCOUNTRY, 2012 – 2018 (USD MN) 43
TABLE 11 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2012 – 2018 (USD MN) 43
TABLE 12 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2013-2019 (USD MN) 48
TABLE 13 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2012 – 2018 (USD MN) 50
TABLE 14 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%) 51
TABLE 15 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%) 52
TABLE 16 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: MERGERS & ACQUISITIONS 53
TABLE 17 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: REGULATORY APPROVALS 53
TABLE 18 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: PARTNERSHIP 54
TABLE 19 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COLLABORATION 54
TABLE 20 BAYER HEALTHCARE AG.: KEY FINANCIALS, 2008 – 2013 (USD MN) 56
TABLE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIALS, 2008 – 2013 (USD MN) 59
TABLE 22 ACTAVIS PLC: KEY FINANCIALS, 2008 – 2013 (USD MN) 62
“”LIST OF FIGURES
FIGURE 1 EVOLUTION OF IUCD 8
FIGURE 2 WIDELY USED CONTRACEPTIVE METHODS 9
FIGURE 3 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: SEGMENTATION & COVERAGE 10
FIGURE 4 INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: INTEGRATED ECOSYSTEM 11
FIGURE 5 TOP-DOWN APPROACH 12
FIGURE 6 BOTTOM-UP APPROACH 13
FIGURE 7 MACRO INDICATOR-BASED APPROACH 14
FIGURE 8 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET SNAPSHOT 17
FIGURE 9 BIRTH CONTROL METHODS COVERED UNDER AFFORDABLE CARE ACT (ACA) 19
FIGURE 10 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPARISON WITH GLOBAL FEMALE CONTRACEPTIVES MARKET 23
FIGURE 11 NORTH AMERICA INTRAUTERINE CONTRACEPTIVE DEVICES, BY COUNTRY,
2013 (USD MN) 24
FIGURE 12 NORTH AMERICA INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2013 (USD MN) 25
FIGURE 13 ADVANTAGES AND DISADVANTAGES OF COPPER IUCD 27
FIGURE 14 ADVANTAGES AND DISADVANTAGES OF HORMONAL IUCD 28
FIGURE 15 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2012 – 2018 (USD MN) 28
FIGURE 16 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET, 2013–2019 (USD MN) 29
FIGURE 17 NORTH AMERICA HORMONAL IUD MARKET, BY COUNTRY, 2013–2019 (USD MN) 30
FIGURE 18 NORTH AMERICA COPPER IUD MARKET, BY COUNTRY, 2013–2019 (USD MN) 31
FIGURE 19 SALES (USD MILLION) OF MIRENA, U.S., 2012 32
FIGURE 20 ADVERSE EFFECTS CAUSED BY MIRENA, U.S., 1997-2012 33
FIGURE 21 PRODUCT COMPARISON BETWEEN MIRENA AND SKYLA, U.S. 36
FIGURE 22 PRODUCT SPECIFICATIONS, LEVOSERT 41
FIGURE 23 AVERAGE SELLING PRICE (USD) OF MARKETED INTRA-UTERINE CONTRACEPTIVE DEVICES (IUCD) IN U.S. AND CANADA, 2013 44
FIGURE 24 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET OVERVIEW,
2014 & 2019 (USD MN) 46
FIGURE 25 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 2013-2019 (USD MN) 47
FIGURE 26 PERCENTAGE USAGE OF VARIOUS CONTRACEPTIVE DEVICES , U.S., 2010 47
FIGURE 27 PERCENTAGE USAGE OF VARIOUS CONTRACEPTIVE DEVICES , U.S., 2013 48
FIGURE 28 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET OVERVIEW,
2013 & 2018 (%) 49
FIGURE 29 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE,
2012-2018 (USD MN) 50
FIGURE 30 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%) 51
FIGURE 31 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%) 52
FIGURE 32 BAYER HEALTHCARE AG: REVENUE MIX (2013) (%) 55
FIGURE 33 CONTRIBUTION OF PHARMACEUTICALS SEGMENT TOWARDS COMPANY REVENUES, 2008-2013 (USD MN) 56
FIGURE 34 TEVA PHARMAVEUTICAL INDUSTRIES LTD.: REVENUE MIX (2013) (%) 59
FIGURE 35 CONTRIBUTION OF SPECIALITY MEDICINE SEGMENT TOWARDS COMPANY REVENUES, 2008-2013 (USD MN) 60
FIGURE 36 ACTAVIS PLC: REVENUE MIX (2013) (%) 62
“
“
